Oncolytics Biotech Inc. (ONC.TO)
CAD 1.1
(-2.65%)
CAD 1.1
(-2.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -33.71 Million CAD | -19.64% |
| 2022 | -26.83 Million CAD | -9.79% |
| 2021 | -25.8 Million CAD | 7.83% |
| 2020 | -25.37 Million CAD | -266.44% |
| 2019 | -20.02 Million CAD | 54.13% |
| 2018 | -16.39 Million CAD | -6.78% |
| 2017 | -15.38 Million CAD | -2.53% |
| 2016 | -14.96 Million CAD | -10.15% |
| 2015 | -13.53 Million CAD | 26.38% |
| 2014 | -18.65 Million CAD | 21.49% |
| 2013 | -23.76 Million CAD | 35.02% |
| 2012 | -36.23 Million CAD | -30.97% |
| 2011 | -28.91 Million CAD | -44.81% |
| 2010 | -24.58 Million CAD | -15.17% |
| 2009 | -15.96 Million CAD | 5.17% |
| 2008 | -17.13 Million CAD | -11.53% |
| 2007 | -15.54 Million CAD | -8.94% |
| 2006 | -13.37 Million CAD | -27.25% |
| 2005 | -12.45 Million CAD | 1.17% |
| 2004 | -12.58 Million CAD | -184.47% |
| 2003 | -5.95 Million CAD | 34.23% |
| 2002 | -6.17 Million CAD | 7.41% |
| 2001 | -6.67 Million CAD | -50.25% |
| 2000 | -4.44 Million CAD | -671.33% |
| 1999 | -575.69 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.82 Million CAD | 9.27% |
| 2024 Q1 | -8.6 Million CAD | 1.49% |
| 2023 FY | - CAD | -18.49% |
| 2023 Q1 | -6.66 Million CAD | 17.72% |
| 2023 Q2 | -6.56 Million CAD | 1.59% |
| 2023 Q4 | -8.74 Million CAD | 25.73% |
| 2023 Q3 | -11.77 Million CAD | -79.34% |
| 2022 Q4 | -8.1 Million CAD | -8.49% |
| 2022 Q3 | -7.47 Million CAD | -8.66% |
| 2022 FY | - CAD | -9.79% |
| 2022 Q1 | -5.72 Million CAD | 19.15% |
| 2022 Q2 | -6.87 Million CAD | -20.09% |
| 2021 Q1 | -5.23 Million CAD | 21.8% |
| 2021 FY | - CAD | 7.83% |
| 2021 Q4 | -7.08 Million CAD | 3.45% |
| 2021 Q3 | -7.33 Million CAD | -22.06% |
| 2021 Q2 | -6 Million CAD | -14.7% |
| 2020 FY | - CAD | -266.44% |
| 2020 Q4 | -6.69 Million CAD | -16.3% |
| 2020 Q3 | -5.76 Million CAD | -39.78% |
| 2020 Q2 | -4.12 Million CAD | 63.42% |
| 2020 Q1 | -11.26 Million CAD | -299.1% |
| 2019 Q1 | -4.84 Million CAD | 0.12% |
| 2019 FY | - CAD | 54.13% |
| 2019 Q4 | 5.65 Million CAD | 276.01% |
| 2019 Q3 | -3.21 Million CAD | 38.1% |
| 2019 Q2 | -5.19 Million CAD | -7.08% |
| 2018 Q2 | -3.66 Million CAD | 21.69% |
| 2018 Q3 | -3.37 Million CAD | 7.97% |
| 2018 FY | - CAD | -6.78% |
| 2018 Q4 | -4.85 Million CAD | -44.04% |
| 2018 Q1 | -4.67 Million CAD | -1.31% |
| 2017 FY | - CAD | -2.53% |
| 2017 Q4 | -4.61 Million CAD | -53.1% |
| 2017 Q3 | -3.01 Million CAD | 30.47% |
| 2017 Q2 | -4.33 Million CAD | -22.38% |
| 2017 Q1 | -3.54 Million CAD | 31.84% |
| 2016 Q3 | -3.32 Million CAD | -29.1% |
| 2016 Q1 | -4.04 Million CAD | -15.8% |
| 2016 FY | - CAD | -10.15% |
| 2016 Q4 | -5.19 Million CAD | -56.61% |
| 2016 Q2 | -2.57 Million CAD | 36.35% |
| 2015 Q4 | -3.48 Million CAD | -23.04% |
| 2015 Q2 | -3.84 Million CAD | -8.02% |
| 2015 Q1 | -3.56 Million CAD | 5.38% |
| 2015 FY | - CAD | 26.38% |
| 2015 Q3 | -2.83 Million CAD | 26.31% |
| 2014 Q3 | -4.63 Million CAD | 1.88% |
| 2014 Q1 | -5.52 Million CAD | 5.11% |
| 2014 Q4 | -3.76 Million CAD | 18.79% |
| 2014 Q2 | -4.72 Million CAD | 14.53% |
| 2014 FY | - CAD | 21.49% |
| 2013 Q2 | -5.09 Million CAD | 23.4% |
| 2013 FY | - CAD | 35.02% |
| 2013 Q4 | -5.82 Million CAD | 5.75% |
| 2013 Q3 | -6.18 Million CAD | -21.25% |
| 2013 Q1 | -6.65 Million CAD | 21.72% |
| 2012 Q1 | -8.55 Million CAD | 24.79% |
| 2012 Q2 | -10.24 Million CAD | -19.83% |
| 2012 FY | - CAD | -30.97% |
| 2012 Q3 | -9.27 Million CAD | 9.45% |
| 2012 Q4 | -8.5 Million CAD | 8.34% |
| 2011 Q3 | -6.31 Million CAD | -9.11% |
| 2011 FY | - CAD | -44.81% |
| 2011 Q1 | -4.04 Million CAD | 45.96% |
| 2011 Q2 | -5.78 Million CAD | -43.03% |
| 2011 Q4 | -11.36 Million CAD | -80.07% |
| 2010 Q4 | -7.48 Million CAD | -86.65% |
| 2010 Q3 | -4.01 Million CAD | 7.73% |
| 2010 Q2 | -4.34 Million CAD | -5.09% |
| 2010 FY | - CAD | -15.17% |
| 2010 Q1 | -4.13 Million CAD | 20.65% |
| 2009 Q3 | -2.68 Million CAD | 36.63% |
| 2009 FY | - CAD | 5.17% |
| 2009 Q1 | -3.86 Million CAD | 17.77% |
| 2009 Q2 | -4.23 Million CAD | -9.43% |
| 2009 Q4 | -5.21 Million CAD | -94.39% |
| 2008 Q4 | -4.7 Million CAD | -15.29% |
| 2008 FY | - CAD | -11.53% |
| 2008 Q1 | -3.22 Million CAD | 35.92% |
| 2008 Q2 | -5.44 Million CAD | -69.01% |
| 2008 Q3 | -4.07 Million CAD | 25.06% |
| 2007 Q2 | -3.81 Million CAD | 8.19% |
| 2007 FY | - CAD | -8.94% |
| 2007 Q4 | -5.02 Million CAD | -44.77% |
| 2007 Q3 | -3.47 Million CAD | 8.92% |
| 2007 Q1 | -4.15 Million CAD | 28.58% |
| 2006 FY | - CAD | -27.25% |
| 2006 Q3 | -3.18 Million CAD | -15.64% |
| 2006 Q2 | -2.75 Million CAD | 1.35% |
| 2006 Q4 | -5.81 Million CAD | -82.7% |
| 2006 Q1 | -2.78 Million CAD | -18.93% |
| 2005 Q1 | -2.13 Million CAD | 43.5% |
| 2005 Q2 | -2.57 Million CAD | -20.44% |
| 2005 FY | - CAD | 1.17% |
| 2005 Q3 | -3.53 Million CAD | -37.07% |
| 2005 Q4 | -2.34 Million CAD | 33.61% |
| 2004 Q1 | -2.59 Million CAD | -28.48% |
| 2004 Q4 | -3.78 Million CAD | -57.77% |
| 2004 Q2 | -3 Million CAD | -16.04% |
| 2004 Q3 | -2.4 Million CAD | 20.18% |
| 2004 FY | - CAD | -184.47% |
| 2003 Q1 | -958.49 Thousand CAD | 38.53% |
| 2003 FY | - CAD | 34.23% |
| 2003 Q4 | -1.75 Million CAD | -21.99% |
| 2003 Q3 | -1.65 Million CAD | -416.46% |
| 2003 Q2 | -1.59 Million CAD | 154.51% |
| 2002 Q1 | -1.3 Million CAD | 16.01% |
| 2002 FY | - CAD | 7.41% |
| 2002 Q4 | -1.55 Million CAD | 17.14% |
| 2002 Q3 | -1.88 Million CAD | -44.75% |
| 2002 Q2 | -1.3 Million CAD | 0.27% |
| 2001 FY | - CAD | -50.25% |
| 2001 Q2 | -1.45 Million CAD | -26.55% |
| 2001 Q3 | -2.51 Million CAD | -72.73% |
| 2001 Q1 | -1.15 Million CAD | -52.92% |
| 2001 Q4 | -1.55 Million CAD | 38.25% |
| 2000 Q1 | -407.77 Thousand CAD | 0.0% |
| 2000 Q2 | -1.53 Million CAD | -277.35% |
| 2000 Q3 | -1.74 Million CAD | -13.21% |
| 2000 Q4 | -752.05 Thousand CAD | 56.83% |
| 2000 FY | - CAD | -671.33% |
| 1999 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -1508.012% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 9.855% |
| Helix BioPharma Corp. | -9.38 Million CAD | -259.037% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 1822.478% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | -80.557% |
| Satellos Bioscience Inc. | -15.7 Million CAD | -114.645% |
| Sernova Corp. | -40.19 Million CAD | 16.13% |